Raloxifene is approved for use in reducing risk of osteoporosis, but not breast cancer
how does clomid work A compound of formula 1 wherein Y is N or CR 12; A is C 6 12 aryl, 5 12 membered heteroaryl, C 3 12 cycloalkyl or 3 12 membered heteroalicyclic, and A is optionally substituted by one or more R 3 groups; R 1 is selected from optionally substituted by one, two or three R 13 groups; R 2 is hydrogen, halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, S O m R 4, SO 2 NR 4 R 5, S O 2 OR 4, NO 2, NR 4 R 5, CR 6 R 7 n OR 4, CN, C O R 4, OC O R 4, O CR 6 R 7 n R 4, NR 4 C O R 5, CR 6 R 7 n C O OR 4, CR 6 R 7 n NCR 4 R 5, C NR 6 NR 4 R 5, NR 4 C O NR 5 R 6, NR 4 S O p R 5 or C O NR 4 R 5, and each hydrogen in R 2 is optionally substituted by R 8; each R 3 is independently halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, S O m R 4, SO 2 NR 4 R 5, S O 2 OR 4, NO 2, NR 4 R 5, CR 6 R 7 OR 4, CN, C O R 4, OC O R 4, O CR 6 R 7 R 4, O CR 6 R 7 CR 6 R 7 n NR 4 R 5, O CR 6 R 7 CR 6 R 7 n OR 4, NR 4 C O R 5, CR 6 R 7 n C O OR 4, CR 6 R 7 n OR 4, CR 6 R 7 n C O NR 4 R 5, CR 6 R 7 n NCR 4 R 5, C NR 6 NR 4 R 5, NR 4 C O NR 5 R 6, NR 4 S O p R 5 or C O NR 4 R 5, each hydrogen in R 3 is optionally substituted by R 8, and R 3 groups on adjacent atoms may combine to form a C 6 12 aryl, 5 12 membered heteroaryl, C 3 12 cycloalkyl or 3 12 membered heteroalicyclic group; each R 4, R 5, R 6 and R 7 is independently hydrogen, halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl; or any two of R 4, R 5, R 6 and R 7 bound to the same nitrogen atom may, together with the nitrogen to which they are bound, be combined to form a 3 to 12 membered heteroalicyclic or 5 12 membered heteroaryl group optionally containing 1 to 3 additional heteroatoms selected from N, O, and S; or any two of R 4, R 5, R 6 and R 7 bound to the same carbon atom may be combined to form a C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic or 5 12 membered heteroaryl group; and each hydrogen in R 4, R 5, R 6 and R 7 is optionally substituted by R 8, or two hydrogen atoms on the same carbon atom in R 4, R 5, R 6 and R 7 is optionally an oxo substituent; each R 8 is independently halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, NH 2, CN, OH, O C 1 12 alkyl, O CH 2 n C 3 12 cycloalkyl, O CH 2 n C 6 12 aryl, O CH 2 n 3 12 membered heteroalicyclic or O CH 2 n 5 12 membered heteroaryl; and each hydrogen in R 8 is optionally substituted by R 11; each R 9 and R 10 is independently hydrogen, halogen, C 1 12 alkyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, S O m R 4, SO 2 NR 4 R 5, S O 2 OR 4, NO 2, NR 4 R 5, CR 6 R 7 n OR 4, CN, C O R 4, OC O R 4, NR 4 C O R 1, CR 6 R 7 n C O OR 4, CR 6 R 7 n NCR 4 R 5, NR 4 C O NR 1 R 6, NR 4 S O p R 5 or C O NR 4 R 5; R 9 or R 10 may combine with a ring atom of A or a substituent of A to form a C 3 12 cycloalkyl, 3 12 membered heteroalicyclic, C 6 12 aryl or 5 12 membered heteroaryl ring fused to A; and each hydrogen in R 9 and R 10 is optionally substituted by R 3; each R 11 is independently halogen, C 1 12 alkyl, C 1 12 alkoxy, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, O C 1 12 alkyl, O CH 2 n C 3 12 cycloalkyl, O CH 2 n C 6 12 aryl, O CH 2 n 3 12 membered heteroalicyclic, O CH 2 n 5 12 membered heteroaryl or CN, and each hydrogen in R 11 is optionally substituted by halogen, OH, CN, C 1 12 alkyl which may be partially or fully halogenated, O C 1 12 alkyl which may be partially or fully halogenated, CO, SO or SO 2; R 12 is hydrogen, halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 12 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, S O m R 4, SO 2 NR 4 R 5, S O 2 OR 4, NO 2, NR 4 R 5, CR 6 R 7 n OR 4, CN, C O R 4, OC O R 4, O CR 6 R 7 n R 4, NR 4 C O R 5, CR 6 R 7 n C O OR 4, CR 6 R 7 n NCR 4 R 5, C NR 6 NR 4 R 5, NR 4 C O NR 5 R 6, NR 4 S O p R 5 or C O NR 4 R 5, and each hydrogen in R 12 is optionally substituted by R 3; each R 13 is independently halogen, C 1 12 alkyl, C 2 12 alkenyl, C 2 12 alkynyl, C 3 12 cycloalkyl, C 6 2 aryl, 3 12 membered heteroalicyclic, 5 12 membered heteroaryl, S O m R 4, SO 2 NR 4 R 5, S O 2 OR 4, NO 2, NR 4 R 5, CR 6 R 7 n OR 4, CN, C O R 4, OC O R 4, O CR 6 R 7 R 4, NR 4 C O R 5, CR 6 R 7 n C O OR 4 CR 6 R 7 n OR 4, CR 6 R 7 n C O NR 4 RR, CR 6 R 7 n NCR 4 R 5, C NR 6 NR 4 R 5, NR 4 C O NR 5 R 6, NR 4 S O p R 5, C O NR 4 R 5, CR 6 R 7 3 12 membered heteroalicyclic, CR 6 R 7 n C 3 12 cycloalkyl, CR 6 R 7 n C 1 12 aryl, CR 6 R 7 n 5 12 membered heteroaryl, CR 6 R 7 n C O NR 4 R 5, or CR 6 R 7 n C O R 4, R 13 groups on adjacent atoms may combine to form a C 6 12 aryl, 5 12 membered heteroaryl, C 3 12 cycloalkyl or 3 12 membered heteroalicyclic group, and each hydrogen in R 13 is optionally substituted by R 3; each m is independently 0, 1 or 2; each n is independently 0, 1, 2, 3 or 4; t is 1, 2, 3 or 4, and each p is independently 1 or 2; or a pharmaceutically acceptable salt, hydrate or solvate thereof, with the proviso that the compound is not 3 1 2, 6 dichloro 3 fluoro phenyl ethoxy 5 1H pyrazol 4 yl pyridin 2 ylamine, 3 1 2, 6 dichloro 3 fluoro phenyl ethoxy 5 1 2 pyrrolidin 1 yl ethyl 1H pyrazol 4 yl pyridin 2 ylamine, 3 1 2, 6 dichloro 3 fluoro phenyl ethoxy 5 1 2 diisopropylamino ethyl 1H pyrazol 4 yl pyridin 2 ylamine, 3 1 2, 6 dichloro 3 fluoro phenyl ethoxy 5 1 2 morpholin 4 yl ethyl 1H pyrazol 4 yl pyridin 2 ylamine or 3 1 2, 6 dichloro 3 fluoro phenyl ethoxy 5 1 methyl 1H pyrazol 4 yl pyridin 2 ylamine
